Since the TyG-CD4 schema relies on glucose and triglyceride values that are already obtained in standard care, it offers a low-cost adjunct to CD4-based evaluation and enables rapid recognition of the highest-risk patients—particularly those with concurrent immunodeficiency and metabolic dysregulation—who may not be identified by CD4 alone. This evidence concerns the gene CD4 and Immunodeficiency.